Sarepta Therapeutics (SRPT) - Stock & Dividends

Sarepta Therapeutics Inc (NASDAQ: SRPT) is a biopharmaceutical company that specializes in developing treatments for rare diseases through RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities. They provide innovative solutions such as EXONDYS 51, VYONDYS 53, and AMONDYS 45 to address duchenne muscular dystrophy caused by specific gene mutations. These medications help patients by enabling exon skipping in the dystrophin gene.

In addition to their current offerings, Sarepta Therapeutics is actively working on expanding their product line. They are in the process of developing SRP-5051, a peptide conjugated PMO targeting exon 51 of dystrophin pre-mRNA, as well as gene therapy programs like SRP-9001 and SRP-9003 for muscular dystrophies. These projects are at various stages of clinical trials, demonstrating the company's commitment to furthering medical advancements in the field.

Collaboration plays a crucial role in Sarepta Therapeutics' success. They have formed partnerships and license agreements with reputable organizations such as F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, and Genevant Sciences among others. These collaborations facilitate research, development, and eventual delivery of life-changing treatments to those in need.

Founded in 1980 and headquartered in Cambridge, Massachusetts, Sarepta Therapeutics continues to be at the forefront of innovation in biopharmaceuticals. For more information about their groundbreaking work, visit their website at https://www.sarepta.com.